Swipe om te navigeren naar een ander artikel
B. Hidvégi and F. Rencz have equally contributed to this work.
Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients.
To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL.
A cross-sectional study has been carried out among adult morphea patients. HRQoL was evaluated by the Dermatology Life Quality Index (DLQI). The modified Localised Scleroderma Skin Severity Index (mLoSSI) and the Localised Scleroderma Damage Index (LoSDI) were applied to evaluate disease activity and damage, respectively. Physician Global Assessment of Activity and Damage (PGA-A, PGA-D) were also completed. Determinants of HRQoL were analysed by multiple regression.
A total of 101 patients (84% females) entered the study, with a mean age of 56.8 ± 14.8 years. Median mLoSSI, LoSDI, PGA-A and PGA-D scores were 8, 5, 9 and 9 points, respectively. Patients with generalised localised (51%) and plaque-type morphea (45%) had median total DLQI scores of 4 and 1, respectively. Embarrassment (53%), itchy or painful skin (46%), and clothing issues (43%) were the most commonly reported problems in the DLQI. Female gender, generalised morphea, higher disease activity (PGA-A score) and involvement of hands and/or feet were significant predictors of impaired HRQoL (p < 0.05).
This study represents the largest sample of adult morphea patients surveyed about their HRQoL in Europe. The frequent occurrence of embarrassment warrants an increased attention to improve patients’ mental health. Care must be taken in case of involvement of functionally sensitive areas, as these cases might require more intensive treatment.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Peterson, L. S., Nelson, A. M., Su, W. P., Mason, T., O’Fallon, W. M., & Gabriel, S. E. (1997). The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. Journal of Rheumatology, 24(1), 73–80. PubMed
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., et al. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401–1424. CrossRefPubMed
Lis-Swiety, A., Janicka, I., Skrzypek-Salamon, A., & Brzezinska-Wcislo, L. (2017). A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Journal of the American Academy of Dermatology, 31(1), 30–37. CrossRef
Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2013). Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychology, Health & Medicine, 18(6), 654–663. CrossRef
Hill, M. K., Kheirandish Pishkenari, A., Braunberger, T. L., Armstrong, A. W., & Dunnick, C. A. (2016). Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. Journal of the American Academy of Dermatology, 75(5), 906–917. CrossRefPubMed
Arkachaisri, T., & Pino, S. (2008). Localized scleroderma severity index and global assessments: A pilot study of outcome instruments. The Journal of Rheumatology, 35(4), 650–657. PubMed
Arkachaisri, T., Vilaiyuk, S., Li, S., O’Neil, K. M., Pope, E., Higgins, G. C., et al. (2009). The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. The Journal of Rheumatology, 36(12), 2819–2829. CrossRefPubMedPubMedCentral
Swinscow, T. D. V., & Campbell, M. J. (2002). Statistics at square one. BMJ: London.
Ardalan, K., Zigler, C. K., & Torok, K. S. (2017). Predictors of longitudinal quality of life in Juvenile localized Scleroderma. Arthritis Care & Research, 69(7), 1082–1087. CrossRef
Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119. CrossRefPubMed
Schmid-Ott, G., Kunsebeck, H. W., Jager, B., Sittig, U., Hofste, N., Ott, R., et al. (2005). Significance of the stigmatization experience of psoriasis patients: A 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Dermato-Venereologica, 85(1), 27–32. CrossRefPubMed
- Association between quality of life and clinical characteristics in patients with morphea
- Springer International Publishing